InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Going where the growth is


DuPont is investing millions of dollars to set up its latest R&D centre in India. Emma Barraclough spoke to the company's chief IP counsel and the director of the Hyderabad-based DuPont Knowledge Center to find out how they plan to tackle the IP challenges ahead

"India rising" has become something of a mantra for the country's leaders as they seek to highlight India's rapid rate of economic growth. But the real test of confidence in an economy is when foreign investment dollars begin to flood in....


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of one week’s FREE access and become a Managing IP member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain 7 days FREE access when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

Re-reading W-L v Actavis patent judgment http://t.co/niQjifQbcg & wondering about likelihood of appeal to @UKSupremeCourt Any views?

May 29 2015 10:40 ·  reply ·  retweet ·  favourite
ManagingIP profile

Wondering how much longer this will take ... #TPP https://t.co/lIqPx5MRLd

May 29 2015 10:27 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @dietmarlen: Th controversial .sucks registry has extended their sunrise phase and delayed the GA phase. Maybe the FTC report has garner…

May 29 2015 10:20 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


INTA Daily News 2015

Read this year's INTA Daily News - published daily by Managing IP direct from the INTA Annual Meeting in San Diego


June 2015

The fine line between abuse and fair use at the PTAB

Hedge fund manager Kyle Bass has outraged the pharma and biotech industries by seeking to invalidate their patents at the PTAB, with some observers linking his attacks to short-selling of company stocks. Michael Loney reports on a controversy that goes to the heart of the US patent system



Most read articles

Supplements